Nan Hu
-
- Lung Cancer Treatments and Mutations 7
- Occupational and environmental lung diseases 4
-
- Cancer Immunotherapy and Biomarkers 14
- Colorectal Cancer Treatments and Studies 4
-
- Cancer Genomics and Diagnostics 3
-
- Chronic Lymphocytic Leukemia Research 3
-
- Esophageal Cancer Research and Treatment 3
-
- Hepatocellular Carcinoma Treatment and Prognosis 3
- Co-authors
- Sonja P. DawseyMiriam R. AnverMark J. RothD RatnasinghePhilip R. TaylorJoseph A. TangreaDavid BalliRobin Cornelissen
- Partner nations
- ChinaUnited StatesJapan
In The Last Decade
Nan Hu
39 papers receiving 577 citations
Hit Papers
Peers
Comparison fields: 5 of 75
- Pulmonary and Respiratory Medicine 297
- Oncology 193
- Pharmacology 82
- Cancer Research 45
- Biotechnology 22
Countries citing papers authored by Nan Hu
This map shows the geographic impact of Nan Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nan Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nan Hu more than expected).
Fields of papers citing papers by Nan Hu
This network shows the impact of papers produced by Nan Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nan Hu. The network helps show where Nan Hu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Nan Hu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2026 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2025 | 2 | |
| 4 | 2024 | 0 | |
| 5 | 2024 | 0 | |
| 6 | 2024 | 6 | |
| 7 | 2024 | 2 | |
| 8 | 2023 | 14 | |
| 9 | 2023 | 2 | |
| 10 | 2023 | 1 | |
| 11 | 2022 | 5 | |
| 12 | 2022 | 0 | |
| 13 | 2022 | 3 | |
| 14 | First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743breakdown → | 2022 | 158 |
| 15 | 2021 | 5 | |
| 16 | 2021 | 7 | |
| 17 | 2019 | 51 | |
| 18 | 2018 | 14 | |
| 19 | 2018 | 9 | |
| 20 | 2014 | 20 |
About Nan Hu
Nan Hu is a scholar working on Oncology, Genetics and Pulmonary and Respiratory Medicine, having authored 45 papers that have together received 584 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (14 papers), Lung Cancer Treatments and Mutations (7 papers), Occupational and environmental lung diseases (4 papers), Colorectal Cancer Treatments and Studies (4 papers), Chronic Lymphocytic Leukemia Research (3 papers), Esophageal Cancer Research and Treatment (3 papers), Cancer Genomics and Diagnostics (3 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (297 citations), Oncology (193 citations) and Pharmacology (82 citations). Nan Hu has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Sonja P. Dawsey, Miriam R. Anver, Mark J. Roth, D Ratnasinghe, Philip R. Taylor, Joseph A. Tangrea, David Balli, Robin Cornelissen, Solange Peters and Sanjay Popat. Their work appears in journals such as Journal of Clinical Oncology, Blood and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.